ATRX Underexpression

CI-VAR-00004410Explore in graph →CIViC 648

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Anaplastic Astrocytoma1
ATRX Underexpression	PCV Regimen + TemozolomideSubstitutes	Predictive	B	Supports Sensitivity Response	3	accepted	EID1647 A retrospective tumor sample study found that the loss of ATRX expression (less than 10% of nuclei) in IDH-mutant astrocytomas treated with temozolomide or a combination of procarbazine, lomustine and… (full text at CIViC) PMID 23904111 · Wiestler et al., 2013 · Open in CIViC	civic
Childhood Low Grade Glioma1
ATRX Underexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID7190 Loss of ATRX was identified in 12 of 247 patients with PLGGs using immunohistochemistry. Survival analysis showed that ATRX loss was associated with adverse overall survival (p<0.0001) and progression…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Glioblastoma1
ATRX Underexpression	(prognostic)	Prognostic	D	Supports Poor Outcome	4	accepted	EID1648 In a glioblastoma mouse model induced by NRAS and p53 knockdown, ATRX loss was associated with a decreased median survival (69 days vs. 84 days; P = .0032). Also, the tumors grew to a larger size at e… (full text at CIViC) PMID 26936505 · Koschmann et al., 2016 · Open in CIViC	civic

Osteosarcoma1
ATRX Underexpression	AZ20 + VE-821Substitutes	Predictive	D	Supports Sensitivity Response	4	submitted	EID5832 Loss of the chromatin-remodeling protein ATRX associates with ALT in cancers. Inhibition of the protein kinase ATR, a critical regulator of recombination recruited by RPA, disrupts ALT and triggers ch… (full text at CIViC) PMID 25593184 · Flynn et al., 2015 · Open in CIViC	civic